期刊文献+

血小板因子4对人肺巨细胞癌细胞系尿激酶和其受体表达的影响 被引量:1

Down- regulated expression of urokinase and receptor in PLA80 1Dlung cancer cells transferred PF4 cDNA
下载PDF
导出
摘要 目的 探讨人血小板因子 4 (hPF4 )抑制血管生成的作用机制。方法 构建含全长hPF4cDNA重组真核表达载体pcDNA3 hPF4 ,将其转染到人肺巨细胞癌细胞系PLA80 1D细胞内 ,应用RT PCR及免疫组化法观察肿瘤细胞自分泌的尿激酶(uPA)及其受体 (uPAR)等的mRNA和蛋白表达水平的变化。结果 导入pcDNA3 hPF4 ,PLA80 1D细胞能稳定表达hPF4mRNA ,其uPA及uPAR的mRNA和蛋白表达水平均明显降低 ,表明hPF4可直接调控uPA及uPAR基因转录 ,影响其蛋白质生物合成。结论 hPF4可直接下调肿瘤细胞自分泌的uPA及uPAR基因转录 ,抑制肿瘤细胞释放uPA及uPAR 。 Objective Tostudytheinhibitingangiogenesismechanismofhumanplateletfactor4 (hPF4 ) .Methods AhPF4genere combinantexpressionvectorwasconstructedbycloninghPF4cDNAintothepcDNA3vector,andwastransferredbylipofectamininto hPF4deficienthumanpulmonarygiantcellcarcinomacellline (PLA80 1D) .ThemRNAandproteinexpressionlevelofPLA80 1D hPF4cellwas detectedbyRT PCRandimmunocytochemistry .Results StableexpressionofhPF4mRNAinPLA80 1D hPF4cellswasconfirmedbyRT PCR .Urokinase typeplasminogenactivator(uPA)andreceptor (uPAR)mRNAandproteinexpressionofPLA80 1D hPF4cellwassignificantly inhibitedcomparedwiththecontrols.TheseresultsdemonstratethattransfectionofhPF4geneintolungcancercellscouldreduceitsuPA、uPAR mRNAexpression ,soitalsoeffectsthecompositionoftheirprotein .Conclusion Thesedataindicatedthatdown regulatedmRNAexpression ofuPA、uPARincancercellscanbeoneofthemechanismsofinhibitingangiogenesisofhPF4 . [
出处 《免疫学杂志》 CAS CSCD 北大核心 2002年第1期51-53,63,共4页 Immunological Journal
关键词 血小板因子4 尿激酶 受体 肺肿瘤 肺巨细胞癌细胞系 plateletfactor4 tumor urokinase typeplasminogenactivatorandreceptor
  • 相关文献

参考文献1

二级参考文献2

共引文献1

同被引文献13

  • 1于津浦,张斌,任秀宝.人重组pMAGE-A1/EGFP真核表达质粒的构建与表达[J].免疫学杂志,2005,21(2):107-110. 被引量:1
  • 2Kim KS,Hong YK,Lee Y,et al.Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains:amino-terminal fragment and kringle domain[J].Exp Mol Med.2003,35(6):578-585.
  • 3Mukhina S,Stepanova V,Traktouev D,et al.The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain.Characterization of interactions and contribution to chemotaxis[J].J Biol Chem,2000,275(22):16 450-16 458.
  • 4Kim KS,Hong YK,Joe YA,et al.Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells[J].J Biol Chem,2003,278(13):11 449-l1 456.
  • 5Blasi F,Vassalli JD,Dano K.Urokinase-type plasminogen activator:proenzyme,receptor,and inhibitors[J].J Cel Biol,1987,104(4):801-804.
  • 6Belin D,Vassalli JD,Combepine C,et al.Cloning,nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator[J].Eur J Biochem,1985,148(2):225-232.
  • 7Duffy MJ.The urokinase plasminogen activator system:role in malignancy[J].Curr Pharm Des,2004,10(1):39-49.
  • 8Lefesvre P,Attema J,van Bekkum D.Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth[J].BMC Cancer,2002,2:17.
  • 9Mohanam S,Chandrasekar N,Yanamandra N,et al.Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator[J].Oncogene,2002,21(51):7 824-7 830.
  • 10Wada M,Wada NA,Shirono H,et al.Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication[J].Biochem Biophys Res Commun,2001,284(2):346-351.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部